{'fraction_non_alphanumeric': 0.020833333333333332, 'fraction_numerical': 0.02666666666666667, 'mean_word_length': 5.035175879396985, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The effect of the immunomodulator agent AS101 on interleukin‐2 production in systemic lupus erythematosus (SLE) induced in mice by a pathogenic anti‐DNA antibody

The role of the synthetic immunomodulator AS101 on the production of interleukin‐2 (IL‐2) by spleen cells of mice with SLE was investigated BALB/c female mice, in which SLE was induced by immunization with the pathogenic idiotype of anti‐DNA antibody 16/6 IJ were treated with AS101 for 7 weeks 2 and 4 months after induction of the disease. The ability of the splenocytes of the mice with SLE to produce IL‐2 was restored after administration of AS101. This effect was particularly impressive when the 7‐week AS101 treatment was initiated 4 months after immunization. Despite its beneficial effect on IL‐2 production. AS101 exerted no influence on the titres of autoatibodies in the sera of the mice. It also had no effect on clinical parameters of SLE, such as the increased sedimentation rate, proteinuria and low white blood cell counts. Our data indicated that defective IL‐2 production in ALE is probably secondary to other disease processes and is not necessarily associated with the production of autoantibodies in this disorder.